Hepion Pharmaceuticals (NASDAQ:HEPA) will present two abstracts for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 taking place June 21 – 24 in Vienna, Austria and digitally.
The first poster, to be presented by Winston Stauffer, Ph.D., of The Scripps Research Institute demonstrates the role of cyclophilin B in the development of NAFLD and NASH (non-alcoholic fatty liver disease and non-alcoholic steatohepatitis) in preclinical models, confirming rencofilstat’s mechanism of action as a cyclophilin inhibitor can offer protection against the development of these diseases.
The second poster, to be presented by Daren Ure, Ph.D., CSO of Hepion, demonstrates that rencofilstat positively changes gene expression networks and lipid profiles in preclinical models toward resolution of NASH.
The changes in gene expression observed in the studies overlapped with the effects of peroxisome proliferator-activated receptors (PPARs) and farnesoid X receptor (FXR) agonists – therapeutics used to treat chronic cholestatic and metabolic liver diseases.
